HUP0302884A2 - Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére - Google Patents

Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére Download PDF

Info

Publication number: HUP0302884A2
Authority: HU; Hungary
Prior art keywords: drug; transporter; virus; medicament; use according
Prior art date: 2000-08-22

Application number

HU0302884A

Other languages

English (en)

Hungarian (hu)

Inventor

Zhi Hong

Johnson Lau

Original Assignee

Ribapharm Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2001-08-21

Publication date

2003-12-29

2001-08-21 Application filed by Ribapharm Inc. filed Critical Ribapharm Inc.

2003-12-29 Publication of HUP0302884A2 publication Critical patent/HUP0302884A2/hu

Links

238000000034 method Methods 0.000 title description 13
210000003494 hepatocyte Anatomy 0.000 title description 9
238000012377 drug delivery Methods 0.000 title description 3
208000004576 Flaviviridae Infections Diseases 0.000 title description 2
239000003814 drug Substances 0.000 claims abstract description 52
210000005229 liver cell Anatomy 0.000 claims abstract description 39
229940079593 drug Drugs 0.000 claims abstract description 37
229960000329 ribavirin Drugs 0.000 claims abstract description 35
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract description 34
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract description 34
230000032258 transport Effects 0.000 claims abstract description 20
210000000170 cell membrane Anatomy 0.000 claims abstract description 14
102000004169 proteins and genes Human genes 0.000 claims abstract description 7
230000003612 virological effect Effects 0.000 claims abstract 4
NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical group N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims description 40
150000001875 compounds Chemical class 0.000 claims description 37
210000004027 cell Anatomy 0.000 claims description 31
239000002777 nucleoside Substances 0.000 claims description 23
150000003833 nucleoside derivatives Chemical class 0.000 claims description 18
241000700605 Viruses Species 0.000 claims description 13
235000000346 sugar Nutrition 0.000 claims description 12
230000001413 cellular effect Effects 0.000 claims description 11
241000710781 Flaviviridae Species 0.000 claims description 10
241000711549 Hepacivirus C Species 0.000 claims description 8
108010052285 Membrane Proteins Proteins 0.000 claims description 7
230000000840 anti-viral effect Effects 0.000 claims description 6
230000001419 dependent effect Effects 0.000 claims description 6
238000001727 in vivo Methods 0.000 claims description 5
102000018697 Membrane Proteins Human genes 0.000 claims description 4
241000710886 West Nile virus Species 0.000 claims description 4
230000000259 anti-tumor effect Effects 0.000 claims description 4
150000003857 carboxamides Chemical class 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
108091005703 transmembrane proteins Proteins 0.000 claims description 4
102000035160 transmembrane proteins Human genes 0.000 claims description 4
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 3
125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
241000710778 Pestivirus Species 0.000 claims description 2
HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 claims description 2
230000001173 tumoral effect Effects 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
206010019695 Hepatic neoplasm Diseases 0.000 claims 2
230000010076 replication Effects 0.000 claims 2
108090000623 proteins and genes Proteins 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 2
239000012528 membrane Substances 0.000 abstract description 2
206010028980 Neoplasm Diseases 0.000 abstract 1
229950006081 taribavirin Drugs 0.000 description 40
108010078791 Carrier Proteins Proteins 0.000 description 15
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
-1 phosphonate ester Chemical class 0.000 description 12
238000002474 experimental method Methods 0.000 description 10
230000000694 effects Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
239000000651 prodrug Substances 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
150000008163 sugars Chemical class 0.000 description 7
208000036142 Viral infection Diseases 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
239000000969 carrier Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 4
102100028524 Lysosomal protective protein Human genes 0.000 description 4
229940047124 interferons Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
102000006992 Interferon-alpha Human genes 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
DYCJFJRCWPVDHY-LSCFUAHRSA-N NBMPR Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(SCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 DYCJFJRCWPVDHY-LSCFUAHRSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
125000003835 nucleoside group Chemical group 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 2
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 2
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
108090000604 Hydrolases Proteins 0.000 description 2
102000004157 Hydrolases Human genes 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
108090000301 Membrane transport proteins Proteins 0.000 description 2
102000003939 Membrane transport proteins Human genes 0.000 description 2
102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229960001614 levamisole Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
108091006527 nucleoside transporters Proteins 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229950009795 tucaresol Drugs 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
MYKLQMNSFPAPLZ-UHFFFAOYSA-N 2,5-dimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C(C)=CC1=O MYKLQMNSFPAPLZ-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
206010014596 Encephalitis Japanese B Diseases 0.000 description 1
WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
108030000917 Glutamine-pyruvate transaminases Proteins 0.000 description 1
241000711557 Hepacivirus Species 0.000 description 1
101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
201000005807 Japanese encephalitis Diseases 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
241000178323 Kokobera virus Species 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000710770 Langat virus Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
201000005805 Murray valley encephalitis Diseases 0.000 description 1
102000019055 Nucleoside Transport Proteins Human genes 0.000 description 1
108091006764 Organic cation transporters Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108091006296 SLC2A1 Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940033350 aclovate Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
229960003099 amcinonide Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940005486 antimigraine preparations Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
229960001102 betamethasone dipropionate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004656 cell transport Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
150000008266 deoxy sugars Chemical class 0.000 description 1
VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical class C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
229940063190 flagyl Drugs 0.000 description 1
229940085863 florone Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940087973 lomotil Drugs 0.000 description 1
229940063175 lotrimin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960003439 mebendazole Drugs 0.000 description 1
BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
102000037831 nucleoside transporters Human genes 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940027035 oxsoralen Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940097191 phazyme Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
SDWIOXKHTFOULX-PDNLFSCWSA-N ribavirin monophosphate Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 SDWIOXKHTFOULX-PDNLFSCWSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229960004546 thiabendazole Drugs 0.000 description 1
WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
235000010296 thiabendazole Nutrition 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
229960003723 tiazofurine Drugs 0.000 description 1
241001147422 tick-borne encephalitis virus group Species 0.000 description 1
229960004880 tolnaftate Drugs 0.000 description 1
FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
229940035306 topicort Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

HU0302884A 2000-08-22 2001-08-21 Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére HUP0302884A2 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22686900P	2000-08-22	2000-08-22
US24062700P	2000-10-13	2000-10-13
PCT/US2001/026057 WO2002015904A1 (en)	2000-08-22	2001-08-21	Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Publications (1)

Publication Number	Publication Date
HUP0302884A2 true HUP0302884A2 (hu)	2003-12-29

Family

ID=26920944

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0302884A HUP0302884A2 (hu)	2000-08-22	2001-08-21	Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére

Country Status (15)

Country	Link
EP (1)	EP1313469A1 (pl)
JP (1)	JP2004506684A (pl)
KR (1)	KR20030040416A (pl)
CN (1)	CN1447692A (pl)
AU (1)	AU2001292557A1 (pl)
BR (1)	BR0113388A (pl)
CA (1)	CA2415793A1 (pl)
CZ (1)	CZ2003308A3 (pl)
HU (1)	HUP0302884A2 (pl)
IL (1)	IL154167A0 (pl)
MX (1)	MXPA03001529A (pl)
NO (1)	NO20030794L (pl)
PL (1)	PL365744A1 (pl)
RU (1)	RU2003102607A (pl)
WO (1)	WO2002015904A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003037908A1 (en) *	2001-10-31	2003-05-08	Ribapharm Inc.	Antiviral combination therapy and compositions
US7608258B2 (en)	2002-04-13	2009-10-27	Allan Mishra	Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) *	2002-04-13	2004-11-02	Allan Mishra	Compositions and minimally invasive methods for treating incomplete connective tissue repair
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
WO2010042658A1 (en)	2008-10-07	2010-04-15	Bioparadox, Llc	Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en)	2013-06-04	2014-12-04	Allan Mishra	Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10449210B2 (en)	2014-02-13	2019-10-22	Ligand Pharmaceuticals Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3984396A (en) *	1971-06-01	1976-10-05	Icn Pharmaceuticals, Inc.	1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) *	1993-05-26	1999-09-28	Laboratori Balducci S.P.A.	Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

2001
- 2001-08-21 CZ CZ2003308A patent/CZ2003308A3/cs unknown
- 2001-08-21 HU HU0302884A patent/HUP0302884A2/hu unknown
- 2001-08-21 WO PCT/US2001/026057 patent/WO2002015904A1/en not_active Ceased
- 2001-08-21 BR BR0113388-8A patent/BR0113388A/pt not_active IP Right Cessation
- 2001-08-21 KR KR10-2003-7002539A patent/KR20030040416A/ko not_active Ceased
- 2001-08-21 RU RU2003102607/15A patent/RU2003102607A/ru not_active Application Discontinuation
- 2001-08-21 EP EP01972926A patent/EP1313469A1/en not_active Withdrawn
- 2001-08-21 CA CA002415793A patent/CA2415793A1/en not_active Abandoned
- 2001-08-21 CN CN01814399A patent/CN1447692A/zh active Pending
- 2001-08-21 PL PL01365744A patent/PL365744A1/pl unknown
- 2001-08-21 MX MXPA03001529A patent/MXPA03001529A/es unknown
- 2001-08-21 IL IL15416701A patent/IL154167A0/xx unknown
- 2001-08-21 AU AU2001292557A patent/AU2001292557A1/en not_active Abandoned
- 2001-08-21 JP JP2002520825A patent/JP2004506684A/ja not_active Withdrawn
2003
- 2003-02-20 NO NO20030794A patent/NO20030794L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20030040416A (ko)	2003-05-22
EP1313469A1 (en)	2003-05-28
CA2415793A1 (en)	2002-02-28
PL365744A1 (pl)	2005-01-10
MXPA03001529A (es)	2004-04-02
WO2002015904B1 (en)	2002-07-04
CN1447692A (zh)	2003-10-08
BR0113388A (pt)	2004-02-25
AU2001292557A1 (en)	2002-03-04
NO20030794L (no)	2003-04-22
NO20030794D0 (no)	2003-02-20
CZ2003308A3 (cs)	2004-03-17
WO2002015904A1 (en)	2002-02-28
RU2003102607A (ru)	2004-07-27
JP2004506684A (ja)	2004-03-04
IL154167A0 (en)	2003-07-31

Publication	Publication Date	Title
US6579857B1 (en)	2003-06-17	Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US20050049220A1 (en)	2005-03-03	Dosing regimen for Flaviviridae therapy
Sofia	2013	Nucleotide prodrugs for the treatment of HCV infection
HUP0302334A2 (hu)	2003-10-28	Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására
JPH06508846A (ja)	1994-10-06	アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
Balzarini et al.	1990	Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2', 3'-dideoxyinosine and 2', 3'-dideoxy-2, 6-diaminopurine riboside
NZ541587A (en)	2008-08-29	Use of adenosine receptor agonists in therapy
Merigan	1991	Treatment of AIDS with combinations of antiretroviral agents
JP2004506684A (ja)	2004-03-04	肝細胞への薬物送達及びフラビウイルス感染症の治療の方法
JPH08503699A (ja)	1996-04-23	全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体
JP2002080490A (ja)	2002-03-19	新規ヌクレオシド
US20040077563A1 (en)	2004-04-22	Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
EP2117563B1 (en)	2012-10-10	Amidinoanthracycline antibiotics for use in the treatment of viral infections
ZA200300649B (en)	2004-04-23	Methods of drug delivery to hepatocytes and treatment of flaviviridae infections.
ES2298229T3 (es)	2008-05-16	Medicamento para el tratamiento de enfermedades causadas por protozoos parasitos.
JP5027809B2 (ja)	2012-09-19	逆転写酵素阻害剤およびメルドニウムに基づく医薬組成物
US8217014B2 (en)	2012-07-10	Pharmaceutical composition for treatment of blood clotting disorder
US8586561B2 (en)	2013-11-19	Anti-tumor agent comprising cytidine derivative and carboplatin
Yoshida et al.	1983	Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors
JP2004155777A (ja)	2004-06-03	Ｃ型慢性肝炎治療剤
Galasso	1988	Promises to keep: clinical use of antiviral drugs
EP1793846A1 (en)	2007-06-13	Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
Upjohn Company	1970	Cytarabine (Cytosar)
MXPA98005083A (en)	1999-07-06	Method of treatment of disorders characterizopopor the over-expression of citidina deaminasa or deoxicitidina deamin
HRP20000421A2 (en)	2000-12-31	Cytokine related treatments of disease